NexgenRx Financial Statements From 2010 to 2026
| NEGXFDelisted Stock | USD 0.20 0.00 0.00% |
Check NexgenRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NexgenRx's main balance sheet or income statement drivers, such as , as well as many indicators such as . NexgenRx financial statements analysis is a perfect complement when working with NexgenRx Valuation or Volatility modules.
NexgenRx |
NexgenRx Company Return On Equity Analysis
NexgenRx's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NexgenRx Return On Equity | 0.4 |
Most of NexgenRx's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NexgenRx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, NexgenRx has a Return On Equity of 0.397. This is 101.66% lower than that of the Insurance sector and significantly higher than that of the Financials industry. The return on equity for all United States stocks is notably lower than that of the firm.
NexgenRx Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NexgenRx's current stock value. Our valuation model uses many indicators to compare NexgenRx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NexgenRx competition to find correlations between indicators driving NexgenRx's intrinsic value. More Info.NexgenRx is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.08 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for NexgenRx is roughly 13.02 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NexgenRx's earnings, one of the primary drivers of an investment's value.About NexgenRx Financial Statements
NexgenRx stakeholders use historical fundamental indicators, such as NexgenRx's revenue or net income, to determine how well the company is positioned to perform in the future. Although NexgenRx investors may analyze each financial statement separately, they are all interrelated. For example, changes in NexgenRx's assets and liabilities are reflected in the revenues and expenses on NexgenRx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NexgenRx. Please read more on our technical analysis and fundamental analysis pages.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada. Nexgenrx operates under Healthcare Plans classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in NexgenRx Pink Sheet
If you are still planning to invest in NexgenRx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NexgenRx's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |